<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39371432</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2632-8682</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>RSC medicinal chemistry</Title><ISOAbbreviation>RSC Med Chem</ISOAbbreviation></Journal><ArticleTitle>Discovery of a nasal spray steroid, tixocortol, as an inhibitor of SARS-CoV-2 main protease and viral replication.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1039/d4md00454j</ELocationID><Abstract><AbstractText>Coronaviruses rely on the viral-encoded chymotrypsin-like main protease (M<sup>pro</sup> or 3CL<sup>pro</sup>) for replication and assembly. Our previous research on M<sup>pro</sup> of SARS-CoV-2 identified cysteine 300 (Cys300) as a potential allosteric site of M<sup>pro</sup> inhibition. Here, we identified tixocortol (TX) as a covalent modifier of Cys300 which inhibits M<sup>pro</sup> activity <i>in vitro</i> as well as in a cell-based M<sup>pro</sup> expression assay. Most importantly TX inhibited SARS-CoV-2 replication in ACE2 expressing HeLa cells. Biochemical analysis and kinetic assays were consistent with TX acting as a non-competitive inhibitor. By contrast, TX was a weaker inhibitor and modifier of C300S M<sup>pro</sup>, confirming a role for Cys300 in inhibition of WT M<sup>pro</sup> but also providing evidence for an additional Cys target. TX pivalate (TP), a prodrug for TX that was previously marketed as a nasal spray, also inhibited SARS-CoV-2 replication in HeLa-ACE2 cells at low micromolar IC<sub>50</sub>s. These studies suggest that TX and/or TP could possibly be repurposed for the prevention and/or treatment of SARS-CoV-2 infection.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>David A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0002-9527-7007</Identifier><AffiliationInfo><Affiliation>HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute Bethesda MD USA david.davis@nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nair</LastName><ForeName>Ashwin</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1338-5344</Identifier><AffiliationInfo><Affiliation>HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute Bethesda MD USA david.davis@nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Astter</LastName><ForeName>Yana</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6277-9687</Identifier><AffiliationInfo><Affiliation>HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute Bethesda MD USA david.davis@nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Treco</LastName><ForeName>Emma</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6634-3717</Identifier><AffiliationInfo><Affiliation>HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute Bethesda MD USA david.davis@nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peyser</LastName><ForeName>Brian</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-3455-5181</Identifier><AffiliationInfo><Affiliation>Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gussio</LastName><ForeName>Rick</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick National Laboratory for Cancer Research Frederick MD 21702 USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Computational Institute for Health and Environmental Research, (CIFHER.ORG) Riverside 5, RM 4076, 8490 Progress Dr. Frederick MD 21701 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Tam</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eaton</LastName><ForeName>Brett</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Integrated Research Facility at Fort Detrick 8200 Research Plaza Frederick MD 21702 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Postnikova</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Integrated Research Facility at Fort Detrick 8200 Research Plaza Frederick MD 21702 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Integrated Research Facility at Fort Detrick 8200 Research Plaza Frederick MD 21702 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shrestha</LastName><ForeName>Prabha</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute Bethesda MD USA david.davis@nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bulut</LastName><ForeName>Haydar</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute Bethesda MD USA david.davis@nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hattorri</LastName><ForeName>Shin-Ichiro</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute 1-21-1 Toyama Shinjuku-ku Tokyo 162-8655 Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitsuya</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute Bethesda MD USA david.davis@nih.gov.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute 1-21-1 Toyama Shinjuku-ku Tokyo 162-8655 Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yarchoan</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3057-1395</Identifier><AffiliationInfo><Affiliation>HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute Bethesda MD USA david.davis@nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RSC Med Chem</MedlineTA><NlmUniqueID>101759460</NlmUniqueID><ISSNLinking>2632-8682</ISSNLinking></MedlineJournalInfo><CoiStatement>D. A. D, Y. A., B. P, R. G., T. N., R. Y. and B. E. are co-inventors on US provisional Patent, U.S. Patent application No. 63/599446 entitled “Tixocortol for use in the Prevention and/or Treatment of Coronavirus Infections”. This invention was made as full-time employees of the US government under 45 Code of Federal Regulations Part 7. All rights, title, and interest to these patents have been or should by law be assigned to the U.S. Department of Health and Human Services. The government conveys a portion of the royalties it receives to its employee inventors under the Federal Technology Transfer Act of 1986 (P. L. 99-502).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>5</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39371432</ArticleId><ArticleId IdType="pmc">PMC11450544</ArticleId><ArticleId IdType="doi">10.1039/d4md00454j</ArticleId><ArticleId IdType="pii">d4md00454j</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Harrison C. M. Doster J. M. Landwehr E. H. Kumar N. P. White E. J. Beachboard D. C. Stobart C. C. Evaluating the Virology and Evolution of Seasonal Human Coronaviruses Associated with the Common Cold in the COVID-19 Era. Microorganisms. 2023;11:445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9961755</ArticleId><ArticleId IdType="pubmed">36838410</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon M. Liang C. Human coronaviruses: The emergence of SARS-CoV-2 and management of COVID-19. Virus Res. 2022;319:198882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9351210</ArticleId><ArticleId IdType="pubmed">35934258</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahboob T. Ismail A. A. Shah M. R. Rahmatullah M. Paul A. K. Pereira M. L. Wiart C. Wilairatana P. Rajagopal M. Dolma K. G. Nissapatorn V. Development of SARS-CoV-2 Vaccine: Challenges and Prospects. Diseases. 2023;11:64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10123684</ArticleId><ArticleId IdType="pubmed">37092446</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews H. S. Herman J. D. Gandhi R. T. Treatments for COVID-19. Annu. Rev. Med. 2024;75:145.</Citation><ArticleIdList><ArticleId IdType="pubmed">37722709</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewitz L. Dumjahn L. Zhao Y. Owen C. D. Laidlaw S. M. Malla T. R. Nguyen D. Lukacik P. Salah E. Crawshaw A. D. Warren A. J. Trincao J. Strain-Damerell C. Carroll M. W. Walsh M. A. Schofield C. J. Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine. J. Med. Chem. 2023;66:2663–2680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9924091</ArticleId><ArticleId IdType="pubmed">36757959</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemian S. M. R. Sheida A. Taghizadieh M. Memar M. Y. Hamblin M. R. Bannazadeh Baghi H. Sadri Nahand J. Asemi Z. Mirzaei H. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? Biomed. Pharmacother. 2023;162:114367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9899776</ArticleId><ArticleId IdType="pubmed">37018987</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin S. A. Banerjee S. Ghosh K. Gayen S. Jha T. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors. Bioorg. Med. Chem. 2021;29:115860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7647411</ArticleId><ArticleId IdType="pubmed">33191083</ArticleId></ArticleIdList></Reference><Reference><Citation>Amani B. Amani B. Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis. J. Med. Virol. 2023;95:e28441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9880713</ArticleId><ArticleId IdType="pubmed">36576379</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D. W. Ju M. J. Wang H. Jia Y. C. Wang X. D. Fang H. Fan J. Proxalutamide for the treatment of COVID-19 rebound following Paxlovid treatment: Report of four cases and review of the literature. J. Clin. Lab. Anal. 2023;37:e24880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10220290</ArticleId><ArticleId IdType="pubmed">37088868</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith-Jeffcoat S. E. Biddle J. E. Talbot H. K. Morrisey K. G. Stockwell M. S. Maldonado Y. McLean H. Q. Ellingson K. D. Bowman N. M. Asturias E. Mellis A. M. Johnson S. Kirking H. L. Rolfes M. A. R. Olivo V. Merrill L. Battan-Wraith S. Sano E. McLaren S. H. Vargas C. Y. Goodman S. Sarnquist C. C. Govindaranjan P. Petrie J. G. Belongia E. A. Ledezma K. Pryor K. Lutrick K. Bullock A. Yang A. Haehnel Q. Rao S. Zhu Y. Schmitz J. Hart K. Grijalva C. G. Salvatore P. P. Symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared to propensity score matched untreated individuals. Clin. Infect. Dis. 2023;78:1175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11090981</ArticleId><ArticleId IdType="pubmed">37963102</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X. Song Y. Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review. Eur. J. Med. Chem. 2023;260:115772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10529944</ArticleId><ArticleId IdType="pubmed">37659195</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H. Bartlam M. Rao Z. Drug design targeting the main protease, the Achilles' heel of coronaviruses. Curr. Pharm. Des. 2006;12:4573–4590.</Citation><ArticleIdList><ArticleId IdType="pubmed">17168763</ArticleId></ArticleIdList></Reference><Reference><Citation>de Souza A. S. de Souza R. F. Guzzo C. R. Quantitative structure-activity relationships, molecular docking and molecular dynamics simulations reveal drug repurposing candidates as potent SARS-CoV-2 main protease inhibitors. J. Biomol. Struct. Dyn. 2022;40:11339–11356.</Citation><ArticleIdList><ArticleId IdType="pubmed">34370631</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen D. R. Allerton C. M. N. Anderson A. S. Aschenbrenner L. Avery M. Berritt S. Boras B. Cardin R. D. Carlo A. Coffman K. J. Dantonio A. Di L. Eng H. Ferre R. Gajiwala K. S. Gibson S. A. Greasley S. E. Hurst B. L. Kadar E. P. Kalgutkar A. S. Lee J. C. Lee J. Liu W. Mason S. W. Noell S. Novak J. J. Obach R. S. Ogilvie K. Patel N. C. Pettersson M. Rai D. K. Reese M. R. Sammons M. F. Sathish J. G. Singh R. S. P. Steppan C. M. Stewart A. E. Tuttle J. B. Updyke L. Verhoest P. R. Wei L. Yang Q. Zhu Y. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586–1593.</Citation><ArticleIdList><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce R. P. Hu V. W. Wang J. The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations. Med. Chem. Res. 2022;31:1637–1646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9425786</ArticleId><ArticleId IdType="pubmed">36060104</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis D. A. Bulut H. Shrestha P. Yaparla A. Jaeger H. K. Hattori S. I. Wingfield P. T. Mieyal J. J. Mitsuya H. Yarchoan R. Regulation of the Dimerization and Activity of SARS-CoV-2 Main Protease through Reversible Glutathionylation of Cysteine 300. MBio. 2021;12:e0209421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8406260</ArticleId><ArticleId IdType="pubmed">34399606</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantrelle F. X. Boll E. Brier L. Moschidi D. Belouzard S. Landry V. Leroux F. Dewitte F. Landrieu I. Dubuisson J. Deprez B. Charton J. Hanoulle X. NMR Spectroscopy of the Main Protease of SARS-CoV-2 and Fragment-Based Screening Identify Three Protein Hotspots and an Antiviral Fragment. Angew. Chem., Int. Ed. 2021;60:25428–25435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8653025</ArticleId><ArticleId IdType="pubmed">34570415</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao X. Zhang L. Du L. Liao R. Cai H. Lu K. Zhao Z. Xie Y. Wang P. H. Pan J. A. Zhang Y. Li G. Dai J. Mao Z. W. Xia W. Allosteric inhibition of SARS-CoV-2 3CL protease by colloidal bismuth subcitrate. Chem. Sci. 2021;12:14098–14102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8565384</ArticleId><ArticleId IdType="pubmed">34760193</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi-Kuwata N. Tsuji K. Hayashi H. Bulut H. Kiso M. Imai M. Ogata-Aoki H. Ishii T. Kobayakawa T. Nakano K. Takamune N. Kishimoto N. Hattori S. I. Das D. Uemura Y. Shimizu Y. Aoki M. Hasegawa K. Suzuki S. Nishiyama A. Saruwatari J. Shimizu Y. Sukenaga Y. Takamatsu Y. Tsuchiya K. Maeda K. Yoshimura K. Iida S. Ozono S. Suzuki T. Okamura T. Misumi S. Kawaoka Y. Tamamura H. Mitsuya H. Identification of SARS-CoV-2 M(pro) inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2. Nat. Commun. 2023;14:1076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9958325</ArticleId><ArticleId IdType="pubmed">36841831</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji K. Ishii T. Kobayakawa T. Higashi-Kuwata N. Azuma C. Nakayama M. Onishi T. Nakano H. Wada N. Hori M. Shinohara K. Miura Y. Kawada T. Hayashi H. Hattori S. I. Bulut H. Das D. Takamune N. Kishimoto N. Saruwatari J. Okamura T. Nakano K. Misumi S. Mitsuya H. Tamamura H. Potent and biostable inhibitors of the main protease of SARS-CoV-2. iScience. 2022;25:105365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9623849</ArticleId><ArticleId IdType="pubmed">36338434</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori S. I. Higashi-Kuwata N. Hayashi H. Allu S. R. Raghavaiah J. Bulut H. Das D. Anson B. J. Lendy E. K. Takamatsu Y. Takamune N. Kishimoto N. Murayama K. Hasegawa K. Li M. Davis D. A. Kodama E. N. Yarchoan R. Wlodawer A. Misumi S. Mesecar A. D. Ghosh A. K. Mitsuya H. A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat. Commun. 2021;12:668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7843602</ArticleId><ArticleId IdType="pubmed">33510133</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K. Y. Krischuns T. Varga L. O. Harigua-Souiai E. Paisant S. Zettor A. Chiaravalli J. Delpal A. Courtney D. O'Brien A. Baker S. C. Decroly E. Isel C. Agou F. Jacob Y. Blondel A. Naffakh N. A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors. Antiviral Res. 2022;201:105272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8906008</ArticleId><ArticleId IdType="pubmed">35278581</ArticleId></ArticleIdList></Reference><Reference><Citation>Larochelle P. Du Souich P. Bolte E. Lelorier J. Goyer R. Tixocortol pivalate, a corticosteroid with no systemic glucocorticoid effect after oral, intrarectal, and intranasal application. Clin. Pharmacol. Ther. 1983;33:343–350.</Citation><ArticleIdList><ArticleId IdType="pubmed">6402333</ArticleId></ArticleIdList></Reference><Reference><Citation>Lelievre V. Junien J. L. Goyer R. Russo-Marie F. Affinity of tixocortol pivalate (JO 1016), tixocortol, cortisol acetate and cortisol for dexamethasone receptors of mouse thymus cells and rat renomedullary interstitial cells in culture. Correlation with their biological activities. J. Steroid Biochem. 1984;20:363–366.</Citation><ArticleIdList><ArticleId IdType="pubmed">6584691</ArticleId></ArticleIdList></Reference><Reference><Citation>Paciaroni A. Libera V. Ripanti F. Orecchini A. Petrillo C. Francisci D. Schiaroli E. Sabbatini S. Gidari A. Bianconi E. Macchiarulo A. Hussain R. Silvestrini L. Moretti P. Belhaj N. Vercelli M. Roque Y. Mariani P. Comez L. Spinozzi F. Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir. Int. J. Mol. Sci. 2023;24:6062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10093836</ArticleId><ArticleId IdType="pubmed">37047038</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori S. I. Higshi-Kuwata N. Raghavaiah J. Das D. Bulut H. Davis D. A. Takamatsu Y. Matsuda K. Takamune N. Kishimoto N. Okamura T. Misumi S. Yarchoan R. Maeda K. Ghosh A. K. Mitsuya H. GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection. MBio. 2020;11:e01833-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7441487</ArticleId><ArticleId IdType="pubmed">32820005</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolini D. Stabile A. M. Bastianelli S. Giustarini D. Pierucci S. Busti C. Vacca C. Gidari A. Francisci D. Castronari R. Mencacci A. Di Cristina M. Focaia R. Sabbatini S. Rende M. Gioiello A. Cruciani G. Rossi R. Galli F. SARS-CoV2 infection impairs the metabolism and redox function of cellular glutathione. Redox Biol. 2021;45:102041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8190457</ArticleId><ArticleId IdType="pubmed">34146958</ArticleId></ArticleIdList></Reference><Reference><Citation>Funk L. M. Poschmann G. Rabe von Pappenheim F. Chari A. Stegmann K. M. Dickmanns A. Wensien M. Eulig N. Paknia E. Heyne G. Penka E. Pearson A. R. Berndt C. Fritz T. Bazzi S. Uranga J. Mata R. A. Dobbelstein M. Hilgenfeld R. Curth U. Tittmann K. Multiple redox switches of the SARS-CoV-2 main protease in vitro provide opportunities for drug design. Nat. Commun. 2024;15:411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10776599</ArticleId><ArticleId IdType="pubmed">38195625</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C. Tan H. Choza J. Wang Y. Wang J. Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays. Acta Pharm. Sin. B. 2022;12:1636–1651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8558150</ArticleId><ArticleId IdType="pubmed">34745850</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C. Hu Y. Townsend J. A. Lagarias P. I. Marty M. T. Kolocouris A. Wang J. Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors. ACS Pharmacol. Transl. Sci. 2020;3:1265–1277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7571300</ArticleId><ArticleId IdType="pubmed">33330841</ArticleId></ArticleIdList></Reference><Reference><Citation>Colado Simao A. N. Perugini Stadtlober N. Stinghen Garcia Lonni A. A. Venancio L. M. Lerner Trigo G. de Souza Cassela P. L. C. Mastellini Sanches Silva T. De Fatima Oliveira Hirth Ruiz M. Batisti Lozovoy M. A. Tano Z. N. da Fonseca Orcina B. Vieira Vilhena F. da Silva Santos P. S. Effect of phthalocyanine oral and nasal antiseptic solutions on the infectivity of SARS-CoV-2 in patients with COVID-19: a randomized controlled trial. Ger. Med. Sci. 2023;21:Doc07.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10326526</ArticleId><ArticleId IdType="pubmed">37426884</ArticleId></ArticleIdList></Reference><Reference><Citation>Klussmann J. P. Grosheva M. Meiser P. Lehmann C. Nagy E. Szijarto V. Nagy G. Konrat R. Flegel M. Holzer F. Gross D. Steinmetz C. Scherer B. Gruell H. Schlotz M. Klein F. de Aragao P. A. Morr H. Al Saleh H. Bilstein A. Russo B. Muller-Scholtz S. Acikel C. Sahin H. Werkhauser N. Allekotte S. Mosges R. Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients. Sci. Rep. 2023;13:6839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10132439</ArticleId><ArticleId IdType="pubmed">37100830</ArticleId></ArticleIdList></Reference><Reference><Citation>Nittayananta W. Lerdsamran H. Chutiwitoonchai N. Promsong A. Srichana T. Netsomboon K. Prasertsopon J. Kerdto J. A novel film spray containing curcumin inhibits SARS-CoV-2 and influenza virus infection and enhances mucosal immunity. Virol. J. 2024;21:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10807123</ArticleId><ArticleId IdType="pubmed">38263162</ArticleId></ArticleIdList></Reference><Reference><Citation>Talotta R. Roberston E. S. Perspectives: potential therapeutic approach with inhalation of ACE2-derived peptides for SARS-CoV-2 infection. Am. J. Clin. Exp. Immunol. 2020;9:73–80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811929</ArticleId><ArticleId IdType="pubmed">33489475</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavda V. P. Baviskar K. P. Vaghela D. A. Raut S. S. Bedse A. P. Nasal sprays for treating COVID-19: a scientific note. Pharmacol. Rep. 2023;75:249–265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9969373</ArticleId><ArticleId IdType="pubmed">36848033</ArticleId></ArticleIdList></Reference><Reference><Citation>Gumowski P. de Gournay C. Girard J. P. Tixocortol pivalate and beclomethasone dipropionate in seasonal allergic rhinitis: a double-blind study. J. Int. Med. Res. 1985;13:328–331.</Citation><ArticleIdList><ArticleId IdType="pubmed">4076531</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanoine F. Grenot C. Sellier N. Barrett W. E. Thompson R. M. Fentiman A. F. Nixon J. R. Goyer R. Junien J. L. Isolation and identification of major metabolites of tixocortol pivalate in human urine. Drug Metab. Dispos. 1987;15:868–876.</Citation><ArticleIdList><ArticleId IdType="pubmed">2893715</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Cruz A. Ruiz-Antoran B. Munoz-Gomez A. Sancho-Lopez A. Mills-Sanchez P. Centeno-Soto G. A. Blanco-Alonso S. Javaloyes-Garachana L. Galan-Gomez A. Valencia-Alijo A. Gomez-Irusta J. Payares-Herrera C. Morras-Torre I. Sanchez-Chica E. Delgado-Tellez-de-Cepeda L. Callejas-Diaz A. Ramos-Martinez A. Munez-Rubio E. Avendano-Sola C. A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality. Antimicrob. Agents Chemother. 2020;64(9) doi: 10.1128/aac.01168-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.01168-20</ArticleId><ArticleId IdType="pmc">PMC7449182</ArticleId><ArticleId IdType="pubmed">32571831</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruzzone C. Bizkarguenaga M. Gil-Redondo R. Diercks T. Arana E. Garcia de Vicuna A. Seco M. Bosch A. Palazon A. San Juan I. Lain A. Gil-Martinez J. Bernardo-Seisdedos G. Fernandez-Ramos D. Lopitz-Otsoa F. Embade N. Lu S. Mato J. M. Millet O. SARS-CoV-2 Infection Dysregulates the Metabolomic and Lipidomic Profiles of Serum. iScience. 2020;23:101645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534591</ArticleId><ArticleId IdType="pubmed">33043283</ArticleId></ArticleIdList></Reference><Reference><Citation>Labarrere C. A. Kassab G. S. Glutathione deficiency in the pathogenesis of SARS-CoV-2 infection and its effects upon the host immune response in severe COVID-19 disease. Front. Microbiol. 2022;13:979719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9582773</ArticleId><ArticleId IdType="pubmed">36274722</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhail S. Zajac J. Fossum C. Lowater H. McCracken C. Severson N. Laatsch B. Narkiewicz-Jodko A. Johnson B. Liebau J. Bhattacharyya S. Hati S. Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review. Protein J. 2020;39:644–656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7587547</ArticleId><ArticleId IdType="pubmed">33106987</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>